Drugs / MenABCWY+¼OMV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01992536 | Dec 2013 → May 2014 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenABCWY+¼OMV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01992536 ↗ |
| Modality | Vaccine | “Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine” NCT01992536 ↗ |